Opendata, web and dolomites

DIALYBRID

Revolutionising the world of hemodialysis with a novel, hybrid, silk fibroin/polyurethane vascular access

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DIALYBRID project word cloud

Explore the words cloud of the DIALYBRID project. It provides you a very rough idea of what is the project "DIALYBRID" about.

54m    semidegradable    nanostructured    interventions    innovative    integration    life    certification    society    commercialization    bottleneck    jobs    materials    meet    hemodialysis    proposes    infective    msca    hypertension    38    validation    urgent    quality    live    2025    reached    ftes    people    diversify    saving    ip    reg    frequent    sme    470    silk    plan    re    reducing    patients    suffer    business    limitations    accesses    sustaining    commercial    portfolio    de    patency    blend    trl    renal    electrospinning    scenario    venture    manufactured    polyurethane    view    risk    human    consequence    complications    increment    sag    2030    opportunity    costly    hybrid    health    alternatives    viability    silkothane    members    industrialization    longer    diabetes    million    functioning    graft    bel    cannulation    master    28    revolutionize    skilled    soundness    fibroin    auspices    enter    clinical    remodeling    action       verify    fact    worldwide    arteriovenous    vascular    trademarked    technological    turnover    global    market    delivering    productivity    36    placement    frequency    therapy    granting    create    competitiveness   

Project "DIALYBRID" data sheet

The following table provides information about the project.

Coordinator
BIOENGINEERING LABORATORIES 

Organization address
address: VIA VIVALDI 32/A
city: CANTU'
postcode: 22063
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.bioengineeringlab.com/eng/sme-instrument-phase-1-dialybrid-december-1-2018/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOENGINEERING LABORATORIES IT (CANTU') coordinator 50˙000.00

Map

 Project objective

Vascular access is the bottleneck to long-term hemodialysis for about 2.2 million people worldwide who need this life-saving/life-sustaining therapy in case of renal failure, e.g. as a consequence of diabetes and/or hypertension. The current alternatives of vascular access suffer in fact from several limitations, e.g. the need for frequent and costly re-interventions, reduced patency, infective complications. To meet this urgent, global, clinical need, BEL proposes SAG (Silkothane® Arteriovenous Graft), an innovative, hybrid, semidegradable, nanostructured vascular access, manufactured by electrospinning using Silkothane®, a silk fibroin/polyurethane blend developed and trademarked by BEL under the auspices of a MSCA action. Enabling early cannulation and easy placement, as well as remodeling, patency, and integration on the long term, SAG will revolutionize the scenario of hemodialysis vascular accesses worldwide by: reducing the frequency of complications and re-interventions (thus health costs); granting broader access to hemodialysis; improving the patients’ quality of life, enabling them to live longer as functioning members of the society. SAG has reached TRL 6. Phase 1 would allow BEL to verify the soundness of SAG’s venture (with a Business Plan and an IP Management Plan), and to de-risk the technological viability of the industrialization (delivering Essential Requirements, Risk Analysis, Validation Master Plan, Industrialization Plan), in view of future clinical studies, certification and commercialization. SAG represents for BEL an important opportunity to diversify its product portfolio, enter the market of Advanced Materials, experience growth in productivity and competitiveness and create new jobs. As the commercial potential of SAG is estimated to be around 28 million € in 2025 and 54M€ in 2030, in 2025 the SME would experience an increment in turnover of about 470%, and a 36% increase (from 28 FTEs to 38 FTEs) in highly skilled human resources.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DIALYBRID" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DIALYBRID" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

RoboSynFarm (2019)

Robotic Synthesis Farm

Read More  

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More